EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter comparative in vitro evaluation of linezolid against recent nosocomial isolates by use of Etest



Multicenter comparative in vitro evaluation of linezolid against recent nosocomial isolates by use of Etest



Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 192



Objective: To evaluate thein vitro activity of linezolid and other antimicrobial agents against recent nosocomial isolates of common Gram-positive bacteria collected in Switzerland. Methods: A representative sample of 473 isolates including resistant strains of Staphylococcus aureus, coagulase-negative staphylococci (CNS), Enterococcus spp., and Streptococcus pneumoniae were collected from various specimens in 5 medical centers from September through November 2000. MICs of linezolid and comparator compounds were determined on site by Etest according to the recommendations of the manufacturer. In order to improve detection of resistance including hereto-resistance, BHI agar, an inoculum of 2.0 McFarland, and 48 h incubation were used for testing enterococci and staphylococci (to vancomycin and teicoplanin only). Results: The MIC90 of linezolid was 2 mg/l for both S. aureus and CNS, independent of oxacillin resistance. Teicoplanin was three times less active against CNS than vancomycin. Linezolid was equally effective against E. faecalis and E. faecium (MIC90 2 and 3 mg/l, respectively). Against pneumococci, linezolid was uniformly active (MIC90 1.5 mg/l) irrespective of resistance to penicillin, ceftriaxone, clarithromycin or clindamycin. Conclusion: Linezolid showed similar activity against various Gram-positive species independent of susceptibility or resistance to other commonly used drugs. Applying the proposed breakpoint of 4 mg/l, no linezolid-resistant strains were detected in this challenging strain collection.

(PDF 0-2 workdays service: $29.90)

Accession: 035349747

Download citation: RISBibTeXText



Related references

In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods. Journal of Antimicrobial ChemoTherapy 47(5): 675-680, 2001

Evaluation or broth microdilution (BMD) and etest (E) for determining in vitro activity of linezolid (LZ) against S-aureus (SA) and enterococci (EN). 2005

Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium. Journal of ChemoTherapy 15(5): 442-448, 2003

Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clinical Infectious Diseases 37(12): 1609-1616, 2003

In vitro activity of linezolid against recent Gram-positive isolates from Belgium. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 194, 2001

Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagnostic Microbiology & Infectious Disease 32(3): 223-227, 1998

Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagnostic Microbiology and Infectious Disease 32(3): 223-227, 1999

Evaluation of the Etest for determining the in-vitro susceptibilities of Prevotella intermedia isolates to metronidazole. Journal of Antimicrobial ChemoTherapy 43(4): 610-611, 1999

Comparative activities of the oxazolidinone AZD2563 and linezolid against selected recent North American isolates of Streptococcus pneumoniae. Antimicrobial Agents and ChemoTherapy 46(9): 3094-3095, 2002

Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid. Clinical Therapeutics 36(9): 1233-1243.E1, 2016

In vitro susceptibility of Cryptococcus neoformans of clinical isolates from aids patients: Comparative study of etest and broth macrodilution methods. Revista de Patologia Tropical 32(2): 215-221, July, 2003

In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: A multicenter sample. Diagnostic Microbiology and Infectious Disease 29(4): 273-276, 1997

In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: a multicenter sample. Diagnostic Microbiology and Infectious Disease 29(4): 273-276, 1998

Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) antimicrobial potency study in Latin America (LA-ZAPS). Brazilian Journal of Infectious Diseases 6(3): 100-109, 2002

In vitro susceptibility of recent isolates of Neisseria gonorrhoeae to cephalosporins of different generations and penicillin G: a comparative evaluation. Dermatologica 168(2): 67-72, 1984